Why AI matters at this scale

Sarepta Therapeutics is a biotechnology company focused on discovering, developing, and commercializing precision genetic medicines for rare diseases, particularly neuromuscular disorders like Duchenne muscular dystrophy (DMD). The company operates in a high-stakes, research-intensive segment where development timelines are long, costs are enormous, and patient populations are small. At a size of 1,001-5,000 employees, Sarepta has the critical mass and financial resources to invest in transformative technologies like artificial intelligence, but must do so strategically to outpace competitors and navigate complex regulatory pathways. AI is not just an efficiency tool here; it is a potential core accelerator for the entire therapeutic pipeline, from initial discovery to post-market optimization.

Concrete AI Opportunities with ROI Framing

1. Accelerating Target Discovery and Validation: The foundational step in genetic medicine is identifying a viable biological target. By deploying AI and machine learning models on integrated multi-omics data (genomics, transcriptomics, proteomics), Sarepta can significantly shorten the target identification phase. These models can uncover novel gene-disease associations and predict the functional impact of genetic interventions. The ROI is measured in years saved in the research phase and increased probability of technical success, directly impacting the value of the preclinical portfolio.

2. Optimizing Clinical Development: Clinical trials for rare diseases are notoriously challenging due to small, heterogeneous patient groups and difficulties in measuring progression. AI can transform this by enabling sophisticated patient stratification using real-world data and predictive biomarkers. Machine learning models can simulate clinical trials to optimize design, select the most responsive patient subgroups, and even create synthetic control arms. This reduces trial duration, lowers patient recruitment costs, and increases the likelihood of demonstrating statistical significance—a direct financial ROI through more efficient capital allocation and higher regulatory approval rates.

3. Enhancing Manufacturing and Supply Chain: Sarepta's therapies, including gene therapies, involve complex biological manufacturing processes. AI-driven process analytical technology (PAT) can monitor bioreactors in real-time, using predictive models to maintain optimal conditions and predict batch quality. This improves yield, consistency, and reduces costly batch failures. For a company at this scale moving into commercial production, even a single-digit percentage increase in manufacturing efficiency translates to millions in annual cost savings and more reliable product supply.

Deployment Risks Specific to This Size Band

At the 1,001-5,000 employee scale, Sarepta faces specific AI deployment risks. First is integration complexity: marrying new AI systems with entrenched legacy R&D, clinical, and manufacturing data platforms can be a major technical hurdle, requiring significant IT and data engineering resources. Second is talent scarcity: attracting and retaining specialized AI talent who also understand biology and drug development is difficult and expensive, competing with larger pharma and tech firms. Third is organizational silos: data and expertise are often fragmented across research, clinical, and commercial divisions, hindering the creation of the unified data lakes needed for powerful AI. Finally, regulatory uncertainty poses a unique risk; using AI to inform drug development decisions introduces questions about model validation, explainability, and auditability that regulators are still grappling with, potentially slowing adoption.